Education
About Us
Working with TipRanks
Follow Us
MediPharm Labs (MEDIF)
OTHER OTC:MEDIF
MEDIF Stock Chart & Stats
$0.05
$0.00(0.00%)
At close: 4:00 PM EST
$0.05
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.09
Previous CloseN/A
Volume94.37K
Average Volume (3M)283.50K
Market Cap
$21.63M
Enterprise Value$19.29M
Total Cash (Recent Filing)$10.58M
Total Debt (Recent Filing)$423.00K
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Apr 01, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding420,755,000
10 Day Avg. Volume139,467
30 Day Avg. Volume283,499
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.57
Price to Sales (P/S)0.58
P/FCF Ratio-4.88
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue0.42
Enterprise Value/Gross Profit1.43
Enterprise Value/Ebitda-3.14
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA near-zero debt-to-equity ratio gives MediPharm durable financial flexibility. Minimal leverage reduces solvency risk through industry cycles, preserves borrowing capacity for capex or M&A, and lowers fixed financial obligations while management works to restore operating profitability.
Proprietary Extraction And Manufacturing CapabilityLeading extraction technology and a contract-manufacturing model create structural advantages: higher product quality, scalable production, and sticky B2B relationships. These capabilities support durable revenue streams, margin protection versus low-cost entrants, and easier market expansion.
Revenue Growth With Improving Gross MarginsModest revenue growth paired with a rising gross margin indicates improving unit economics and operational leverage. If sustained, this trend supports long-term margin recovery and the potential to translate top-line gains into operating profitability as fixed costs are absorbed.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow is a structural weakness: the business is not generating cash from core operations, which undermines self-funding of growth, increases reliance on external capital, and raises execution risk if market or funding conditions tighten.
Persistent Net Losses And Negative MarginsSustained negative net and EBIT margins highlight a structural profitability gap. Despite gross margin gains, elevated operating expenses or scale shortfalls prevent positive earnings, impeding retained earnings accumulation and making achieving durable shareholder returns more uncertain.
Negative Return On EquityA -20% ROE signals the company is destroying shareholder value rather than creating it. This structural metric reflects persistent losses and weak capital efficiency, making it harder to attract investment and prolonging the timeline to meaningful recovery even if revenue trends improve.
MediPharm Labs News
MEDIF FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was $0.04 and its highest was $0.09 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is $21.63M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Apr 01, 2026 which is in 44 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on Nov 13, 2025. The company reported -$0.007 earnings per share for the quarter, missing the consensus estimate of -$0.002 by -$0.005.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is 0.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 420,755,000 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of -$0.007 in its last earnings report, missing expectations of -$0.002. Following the earnings report the stock price went down -5.769%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in MEDIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
MEDIF Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects positive trends in financial performance, especially with record gross profit and strong international growth. However, it is overshadowed by challenges in the Canadian market and significant concerns over activist shareholder issues. This creates a mixed outlook, with strong operational performance but potential strategic risks.View all MEDIF earnings summariesTechnical Analysis
Ownership Overview
Options Prices
Currently, No data available
---